I find looking up the technical information about my clinical trial and the medications involved fascinating. I may not understand the majority of it but every once in a while I’ll find a summary of an article which will help translate a lot of the medical jargon. Only my friends who are doctors will probably care about the rest of this…
This evening I happened across the clinical trial I’ll be participating in at the ClinicalTrials.gov website which is part of NIH. The study is: NCT02646748, and is titled: Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
I’ll be participating in the Pembrolizumab with INCB039110 portion of the study.
Pembrolizumab has already passed FDA approval and is prescribed as Keytruda by Merck.
INCB039110 is a JAK1 inhibitor. I found it referred to as Itacitinib at a site called MedChem Express.
And now you know more than you ever cared to know.